Global Proteasome Inhibitors Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	173 Pages	TechNavio	December, 2023	INF18391879

Best Price Guarantee
Price	from $2,500
Length	173 Pages
Publisher	TechNavio
Published Date	December, 2023
SKU	INF18391879

Global Proteasome Inhibitors Market 2024-2028

The proteasome inhibitors market is forecasted to grow by USD 2.91 bn during 2023-2028, accelerating at a CAGR of 7.48% during the forecast period. The report on the proteasome inhibitoars market provides a holistic analysis, market size, and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by a huge unmet need for certain cancer therapeutics, strong adoption rate, and growing prevalence of multiple myeloma.

Technavio's proteasome inhibitors market is segmented as below:

By Route Of Administration

Oral
Intravenous

By Product

VELCADE
KYPROLIS
NINLARO
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the expanded application of proteasome inhibitors as one of the prime reasons driving the proteasome inhibitors market growth during the next few years. Also, special drug designation for proteasome inhibitors by regulatory agencies and high market growth potential in developing economies will lead to sizable demand in the market.

The report on the proteasome inhibitors market covers the following areas:

Proteasome inhibitors market sizing
Proteasome inhibitors market forecast
Proteasome inhibitors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors market vendors that include Amgen Inc., Baxter International Inc., Bio Techne Corp., Bristol Myers Squibb Co., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Kezar Life Sciences Inc., LifeSensors Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., QLi5 Therapeutics, Takeda Pharmaceutical Co. Ltd., TG Therapeutics Inc., and Thermo Fisher Scientific Inc.. Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape; Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibit 06: Executive Summary - Chart on Market Segmentation by Product; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global proteasome inhibitors market 2018 - 2022; Exhibit 18: Historic Market Size - Data Table on global proteasome inhibitors market 2018 - 2022 ($ billion); 4.2 Route Of Administration Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion); 4.3 Product Segment Analysis 2018 - 2022; Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ billion); 4.4 Geography Segment Analysis 2018 - 2022; Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); 4.5 Country Segment Analysis 2018 - 2022; Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 23: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration: 6.1 Market segments; Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%); Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%); 6.2 Comparison by Route of Administration; Exhibit 32: Chart on Comparison by Route of Administration; Exhibit 33: Data Table on Comparison by Route of Administration; 6.3 Oral - Market size and forecast 2023-2028; Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion); Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion); Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%); 6.4 Intravenous - Market size and forecast 2023-2028; Exhibit 38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion); Exhibit 39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion); Exhibit 40: Chart on Intravenous - Year-over-year growth 2023-2028 (%); Exhibit 41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Route of Administration; Exhibit 42: Market opportunity by Route of Administration ($ billion); Exhibit 43: Data Table on Market opportunity by Route of Administration ($ billion)
7 Market Segmentation by Product: 7.1 Market segments; Exhibit 44: Chart on Product - Market share 2023-2028 (%); Exhibit 45: Data Table on Product - Market share 2023-2028 (%); 7.2 Comparison by Product; Exhibit 46: Chart on Comparison by Product; Exhibit 47: Data Table on Comparison by Product; 7.3 VELCADE - Market size and forecast 2023-2028; Exhibit 48: Chart on VELCADE - Market size and forecast 2023-2028 ($ billion); Exhibit 49: Data Table on VELCADE - Market size and forecast 2023-2028 ($ billion); Exhibit 50: Chart on VELCADE - Year-over-year growth 2023-2028 (%); Exhibit 51: Data Table on VELCADE - Year-over-year growth 2023-2028 (%); 7.4 KYPROLIS - Market size and forecast 2023-2028; Exhibit 52: Chart on KYPROLIS - Market size and forecast 2023-2028 ($ billion); Exhibit 53: Data Table on KYPROLIS - Market size and forecast 2023-2028 ($ billion); Exhibit 54: Chart on KYPROLIS - Year-over-year growth 2023-2028 (%); Exhibit 55: Data Table on KYPROLIS - Year-over-year growth 2023-2028 (%); 7.5 NINLARO - Market size and forecast 2023-2028; Exhibit 56: Chart on NINLARO - Market size and forecast 2023-2028 ($ billion); Exhibit 57: Data Table on NINLARO - Market size and forecast 2023-2028 ($ billion); Exhibit 58: Chart on NINLARO - Year-over-year growth 2023-2028 (%); Exhibit 59: Data Table on NINLARO - Year-over-year growth 2023-2028 (%); 7.6 Others - Market size and forecast 2023-2028; Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%); 7.7 Market opportunity by Product; Exhibit 64: Market opportunity by Product ($ billion); Exhibit 65: Data Table on Market opportunity by Product ($ billion)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Exhibit 69: Chart on Geographic comparison; Exhibit 70: Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%); Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 Japan - Market size and forecast 2023-2028; Exhibit 91: Chart on Japan - Market size and forecast 2023-2028 ($ billion); Exhibit 92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion); Exhibit 93: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibit 94: Data Table on Japan - Year-over-year growth 2023-2028 (%); 9.9 UK - Market size and forecast 2023-2028; Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%); 9.10 Canada - Market size and forecast 2023-2028; Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ billion); Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion); Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.11 Germany - Market size and forecast 2023-2028; Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Exhibit 107: Market opportunity By Geographical Landscape ($ billion); Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion); 10 Drivers, Challenges, and Trends; 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 109: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends; 11 Vendor Landscape; 11.1 Overview; 11.2 Vendor landscape; Exhibit 110: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 111: Overview on factors of disruption; 11.4 Industry risks; Exhibit 112: Impact of key risks on business; 12 Vendor Analysis; 12.1 Vendors covered; Exhibit 113: Vendors covered; 12.2 Market positioning of vendors; Exhibit 114: Matrix on vendor position and classification; 12.3 Amgen Inc.; Exhibit 115: Amgen Inc. - Overview; Exhibit 116: Amgen Inc. - Product / Service; Exhibit 117: Amgen Inc. - Key offerings; 12.4 Baxter International Inc.; Exhibit 118: Baxter International Inc. - Overview; Exhibit 119: Baxter International Inc. - Business segments; Exhibit 120: Baxter International Inc. - Key news; Exhibit 121: Baxter International Inc. - Key offerings; Exhibit 122: Baxter International Inc. - Segment focus; 12.5 Bio Techne Corp.; Exhibit 123: Bio Techne Corp. - Overview; Exhibit 124: Bio Techne Corp. - Business segments; Exhibit 125: Bio Techne Corp. - Key offerings; Exhibit 126: Bio Techne Corp. - Segment focus; 12.6 Bristol Myers Squibb Co.; Exhibit 127: Bristol Myers Squibb Co. - Overview; Exhibit 128: Bristol Myers Squibb Co. - Product / Service; Exhibit 129: Bristol Myers Squibb Co. - Key news; Exhibit 130: Bristol Myers Squibb Co. - Key offerings; 12.7 Fresenius SE and Co. KGaA; Exhibit 131: Fresenius SE and Co. KGaA - Overview; Exhibit 132: Fresenius SE and Co. KGaA - Business segments; Exhibit 133: Fresenius SE and Co. KGaA - Key news; Exhibit 134: Fresenius SE and Co. KGaA - Key offerings; Exhibit 135: Fresenius SE and Co. KGaA - Segment focus; 12.8 Johnson and Johnson; Exhibit 136: Johnson and Johnson - Overview; Exhibit 137: Johnson and Johnson - Business segments; Exhibit 138: Johnson and Johnson - Key news; Exhibit 139: Johnson and Johnson - Key offerings; Exhibit 140: Johnson and Johnson - Segment focus; 12.9 Kezar Life Sciences Inc.; Exhibit 141: Kezar Life Sciences Inc. - Overview; Exhibit 142: Kezar Life Sciences Inc. - Product / Service; Exhibit 143: Kezar Life Sciences Inc. - Key news; Exhibit 144: Kezar Life Sciences Inc. - Key offerings; 12.10 LifeSensors Inc.; Exhibit 145: LifeSensors Inc. - Overview; Exhibit 146: LifeSensors Inc. - Product / Service; Exhibit 147: LifeSensors Inc. - Key offerings; 12.11 Merck and Co. Inc.; Exhibit 148: Merck and Co. Inc. - Overview; Exhibit 149: Merck and Co. Inc. - Business segments; Exhibit 150: Merck and Co. Inc. - Key news; Exhibit 151: Merck and Co. Inc. - Key offerings; Exhibit 152: Merck and Co. Inc. - Segment focus; 12.12 Novartis AG; Exhibit 153: Novartis AG - Overview; Exhibit 154: Novartis AG - Business segments; Exhibit 155: Novartis AG - Key offerings; Exhibit 156: Novartis AG - Segment focus; 12.13 Pfizer Inc.; Exhibit 157: Pfizer Inc. - Overview; Exhibit 158: Pfizer Inc. - Product / Service; Exhibit 159: Pfizer Inc. - Key news; Exhibit 160: Pfizer Inc. - Key offerings; 12.14 QLi5 Therapeutics; Exhibit 161: QLi5 Therapeutics - Overview; Exhibit 162: QLi5 Therapeutics - Product / Service; Exhibit 163: QLi5 Therapeutics - Key offerings; 12.15 Takeda Pharmaceutical Co. Ltd.; Exhibit 164: Takeda Pharmaceutical Co. Ltd. - Overview; Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Product / Service; Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Key news; Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key offerings; 12.16 TG Therapeutics Inc.; Exhibit 168: TG Therapeutics Inc. - Overview; Exhibit 169: TG Therapeutics Inc. - Product / Service; Exhibit 170: TG Therapeutics Inc. - Key offerings; 12.17 Thermo Fisher Scientific Inc.; Exhibit 171: Thermo Fisher Scientific Inc. - Overview; Exhibit 172: Thermo Fisher Scientific Inc. - Business segments; Exhibit 173: Thermo Fisher Scientific Inc. - Key news; Exhibit 174: Thermo Fisher Scientific Inc. - Key offerings; Exhibit 175: Thermo Fisher Scientific Inc. - Segment focus; 13 Appendix; 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 176: Inclusions checklist; Exhibit 177: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 178: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 179: Research methodology; Exhibit 180: Validation techniques employed for market sizing; Exhibit 181: Information sources; 13.5 List of abbreviations; Exhibit 182: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits6: Executive Summary - Chart on Market Segmentation by Product; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Vendor Market Positioning; Exhibits10: Parent market; Exhibits11: Market Characteristics; Exhibits12: Offerings of vendors included in the market definition; Exhibits13: Market segments; Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits18: Historic Market Size - Data Table on global proteasome inhibitors market 2018 - 2022 ($ billion); Exhibits19: Historic Market Size - Route Of Administration Segment 2018 - 2022 ($ billion); Exhibits20: Historic Market Size - Product Segment 2018 - 2022 ($ billion); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion); Exhibits23: Five forces analysis - Comparison between 2023 and 2028; Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits29: Chart on Market condition - Five forces 2023 and 2028; Exhibits30: Chart on Route of Administration - Market share 2023-2028 (%); Exhibits31: Data Table on Route of Administration - Market share 2023-2028 (%); Exhibits32: Chart on Comparison by Route of Administration; Exhibits33: Data Table on Comparison by Route of Administration; Exhibits34: Chart on Oral - Market size and forecast 2023-2028 ($ billion); Exhibits35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion); Exhibits36: Chart on Oral - Year-over-year growth 2023-2028 (%); Exhibits37: Data Table on Oral - Year-over-year growth 2023-2028 (%); Exhibits38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion); Exhibits39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion); Exhibits40: Chart on Intravenous - Year-over-year growth 2023-2028 (%); Exhibits41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%); Exhibits42: Market opportunity by Route of Administration ($ billion); Exhibits43: Data Table on Market opportunity by Route of Administration ($ billion); Exhibits44: Chart on Product - Market share 2023-2028 (%); Exhibits45: Data Table on Product - Market share 2023-2028 (%); Exhibits46: Chart on Comparison by Product; Exhibits47: Data Table on Comparison by Product; Exhibits48: Chart on VELCADE - Market size and forecast 2023-2028 ($ billion); Exhibits49: Data Table on VELCADE - Market size and forecast 2023-2028 ($ billion); Exhibits50: Chart on VELCADE - Year-over-year growth 2023-2028 (%); Exhibits51: Data Table on VELCADE - Year-over-year growth 2023-2028 (%); Exhibits52: Chart on KYPROLIS - Market size and forecast 2023-2028 ($ billion); Exhibits53: Data Table on KYPROLIS - Market size and forecast 2023-2028 ($ billion); Exhibits54: Chart on KYPROLIS - Year-over-year growth 2023-2028 (%); Exhibits55: Data Table on KYPROLIS - Year-over-year growth 2023-2028 (%); Exhibits56: Chart on NINLARO - Market size and forecast 2023-2028 ($ billion); Exhibits57: Data Table on NINLARO - Market size and forecast 2023-2028 ($ billion); Exhibits58: Chart on NINLARO - Year-over-year growth 2023-2028 (%); Exhibits59: Data Table on NINLARO - Year-over-year growth 2023-2028 (%); Exhibits60: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibits61: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibits62: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits63: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits64: Market opportunity by Product ($ billion); Exhibits65: Data Table on Market opportunity by Product ($ billion); Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits69: Chart on Geographic comparison; Exhibits70: Data Table on Geographic comparison; Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits91: Chart on Japan - Market size and forecast 2023-2028 ($ billion); Exhibits92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion); Exhibits93: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibits94: Data Table on Japan - Year-over-year growth 2023-2028 (%); Exhibits95: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibits96: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibits97: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits98: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits99: Chart on Canada - Market size and forecast 2023-2028 ($ billion); Exhibits100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion); Exhibits101: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits102: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits103: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits105: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits106: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits107: Market opportunity By Geographical Landscape ($ billion); Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ billion); Exhibits109: Impact of drivers and challenges in 2023 and 2028; Exhibits110: Overview on Criticality of inputs and Factors of differentiation; Exhibits111: Overview on factors of disruption; Exhibits112: Impact of key risks on business; Exhibits113: Vendors covered; Exhibits114: Matrix on vendor position and classification; Exhibits115: Amgen Inc. - Overview; Exhibits116: Amgen Inc. - Product / Service; Exhibits117: Amgen Inc. - Key offerings; Exhibits118: Baxter International Inc. - Overview; Exhibits119: Baxter International Inc. - Business segments; Exhibits120: Baxter International Inc. - Key news; Exhibits121: Baxter International Inc. - Key offerings; Exhibits122: Baxter International Inc. - Segment focus; Exhibits123: Bio Techne Corp. - Overview; Exhibits124: Bio Techne Corp. - Business segments; Exhibits125: Bio Techne Corp. - Key offerings; Exhibits126: Bio Techne Corp. - Segment focus; Exhibits127: Bristol Myers Squibb Co. - Overview; Exhibits128: Bristol Myers Squibb Co. - Product / Service; Exhibits129: Bristol Myers Squibb Co. - Key news; Exhibits130: Bristol Myers Squibb Co. - Key offerings; Exhibits131: Fresenius SE and Co. KGaA - Overview; Exhibits132: Fresenius SE and Co. KGaA - Business segments; Exhibits133: Fresenius SE and Co. KGaA - Key news; Exhibits134: Fresenius SE and Co. KGaA - Key offerings; Exhibits135: Fresenius SE and Co. KGaA - Segment focus; Exhibits136: Johnson and Johnson - Overview; Exhibits137: Johnson and Johnson - Business segments; Exhibits138: Johnson and Johnson - Key news; Exhibits139: Johnson and Johnson - Key offerings; Exhibits140: Johnson and Johnson - Segment focus; Exhibits141: Kezar Life Sciences Inc. - Overview; Exhibits142: Kezar Life Sciences Inc. - Product / Service; Exhibits143: Kezar Life Sciences Inc. - Key news; Exhibits144: Kezar Life Sciences Inc. - Key offerings; Exhibits145: LifeSensors Inc. - Overview; Exhibits146: LifeSensors Inc. - Product / Service; Exhibits147: LifeSensors Inc. - Key offerings; Exhibits148: Merck and Co. Inc. - Overview; Exhibits149: Merck and Co. Inc. - Business segments; Exhibits150: Merck and Co. Inc. - Key news; Exhibits151: Merck and Co. Inc. - Key offerings; Exhibits152: Merck and Co. Inc. - Segment focus; Exhibits153: Novartis AG - Overview; Exhibits154: Novartis AG - Business segments; Exhibits155: Novartis AG - Key offerings; Exhibits156: Novartis AG - Segment focus; Exhibits157: Pfizer Inc. - Overview; Exhibits158: Pfizer Inc. - Product / Service; Exhibits159: Pfizer Inc. - Key news; Exhibits160: Pfizer Inc. - Key offerings; Exhibits161: QLi5 Therapeutics - Overview; Exhibits162: QLi5 Therapeutics - Product / Service; Exhibits163: QLi5 Therapeutics - Key offerings; Exhibits164: Takeda Pharmaceutical Co. Ltd. - Overview; Exhibits165: Takeda Pharmaceutical Co. Ltd. - Product / Service; Exhibits166: Takeda Pharmaceutical Co. Ltd. - Key news; Exhibits167: Takeda Pharmaceutical Co. Ltd. - Key offerings; Exhibits168: TG Therapeutics Inc. - Overview; Exhibits169: TG Therapeutics Inc. - Product / Service; Exhibits170: TG Therapeutics Inc. - Key offerings; Exhibits171: Thermo Fisher Scientific Inc. - Overview; Exhibits172: Thermo Fisher Scientific Inc. - Business segments; Exhibits173: Thermo Fisher Scientific Inc. - Key news; Exhibits174: Thermo Fisher Scientific Inc. - Key offerings; Exhibits175: Thermo Fisher Scientific Inc. - Segment focus; Exhibits176: Inclusions checklist; Exhibits177: Exclusions checklist; Exhibits178: Currency conversion rates for US$; Exhibits179: Research methodology; Exhibits180: Validation techniques employed for market sizing; Exhibits181: Information sources; Exhibits182: List of abbreviations